Renal function trajectories before and during the COVID-19 pandemic in Japanese individuals with type 1 diabetes: a post-hoc analysis of the multicenter retrospective investigation by the IPRA-CKD study group
Abstract
The coronavirus disease 2019 (COVID-19) pandemic and associated lifestyle changes have affected metabolic status in individuals with diabetes. The impact of these changes on renal function in individuals with type 1 diabetes (T1D) remains unclear. We performed a post-hoc analysis of a multicenter retrospective cohort study (the IPRA-CKD study) including 190 Japanese individuals with T1D who were not receiving sodium–glucose cotransporter 2 inhibitors. Participants were recruited between June 2022 and July 2023, and longitudinal data over a consecutive 60-month period preceding enrollment were extracted at 6-month intervals and divided into periods before and during the pandemic. Annual rates of estimated glomerular filtration rate (eGFR) decline were compared between the periods before and during the COVID-19 pandemic using a linear mixed-effects model. The eGFR decline was not accelerated during the pandemic compared with before the pandemic; the estimated eGFR slopes were –1.54 ± 0.28 mL/min/1.73 m2/year before the pandemic and –1.05 ± 0.22 mL/min/1.73 m2/year during the pandemic (p = 0.27). Glycemic control was preserved during the pandemic, despite small but significant increases in body weight, blood pressure, and insulin dose. Exploratory subgroup analyses suggested a less steep eGFR decline during the pandemic among participants with body mass index ≥25 kg/m2 or those receiving renin–angiotensin system inhibitors; however, these findings should be interpreted as hypothesis-generating. In this multicenter cohort of individuals with T1D, the COVID-19 pandemic was not associated with accelerated eGFR decline overall.
Related
- Kidney Function Trajectories in Patients with and Without Chronic Kidney Disease Undergoing Transcatheter Aortic Valve Replacement: A Single-Retrospective Cohort Study
- Long‐term effects of tofogliflozin on renal function in patients with type 2 diabetes: A retrospective multicenter study
- Brain gray matter changes across chronic pain trajectories: MRI evidence from 35,000 individuals
- The lived experiences of sexual and gender minority individuals in Guyana: a qualitative investigation into well-being
- Investigation of the Number of Falls and Fall Risk Factors in Geriatric Individuals Living in a Nursing Home
BibTeX
@article{nakamura2026renal,
title = {{Renal function trajectories before and during the COVID-19 pandemic in Japanese individuals with type 1 diabetes: a post-hoc analysis of the multicenter retrospective investigation by the IPRA-CKD study group}},
author = {Yuta Nakamura and Hiroshi Yano and Norio Abiru and Hiroshi Nomoto and Tomoyasu Fukui and Yoshihiko Yuyama and Tomoyuki Kawamura and Mariko Ueda and Akane Yamamoto and Yushi Hirota and Yoshiki Kusunoki and Kenro Nishida and Dan Sekiguchi and Yasutaka Maeda and Masae Minami and Ayako Nagayama and Shimpei Iwata and Hitomi Minagawa and Shinya Furukawa and Teruki Miyake and Hiroaki Ueno and Rei Chinen and Yoshiro Nakayama and Hiroaki Masuzaki and Yasutaka Miyachi and Yosuke Okada and Mitsuhiro Okamoto and Kaoru Ono and Ken-ichi Tanaka and Akira Kurozumi and Takenori Sakai and Hironori Yamasaki and Jun-ichi Yasui and Ayako Ito and Ichiro Horie},
journal = {Endocrine Journal},
year = {2026},
month = sep,
doi = {10.1507/endocrj.ej26-0257},
url = {https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ26-0257/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Renal function trajectories before and during the COVID-19 pandemic in Japanese individuals with type 1 diabetes: a post-hoc analysis of the multicenter retrospective investigation by the IPRA-CKD study group
AU - Yuta Nakamura
AU - Hiroshi Yano
AU - Norio Abiru
AU - Hiroshi Nomoto
AU - Tomoyasu Fukui
AU - Yoshihiko Yuyama
AU - Tomoyuki Kawamura
AU - Mariko Ueda
AU - Akane Yamamoto
AU - Yushi Hirota
AU - Yoshiki Kusunoki
AU - Kenro Nishida
AU - Dan Sekiguchi
AU - Yasutaka Maeda
AU - Masae Minami
AU - Ayako Nagayama
AU - Shimpei Iwata
AU - Hitomi Minagawa
AU - Shinya Furukawa
AU - Teruki Miyake
AU - Hiroaki Ueno
AU - Rei Chinen
AU - Yoshiro Nakayama
AU - Hiroaki Masuzaki
AU - Yasutaka Miyachi
AU - Yosuke Okada
AU - Mitsuhiro Okamoto
AU - Kaoru Ono
AU - Ken-ichi Tanaka
AU - Akira Kurozumi
AU - Takenori Sakai
AU - Hironori Yamasaki
AU - Jun-ichi Yasui
AU - Ayako Ito
AU - Ichiro Horie
PY - 2026
DA - 2026/09/30
JO - Endocrine Journal
DO - 10.1507/endocrj.ej26-0257
UR - https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ26-0257/_article
AB - The coronavirus disease 2019 (COVID-19) pandemic and associated lifestyle changes have affected metabolic status in individuals with diabetes. The impact of these changes on renal function in individuals with type 1 diabetes (T1D) remains unclear. We performed a post-hoc analysis of a multicenter retrospective cohort study (the IPRA-CKD study) including 190 Japanese individuals with T1D who were not receiving sodium–glucose cotransporter 2 inhibitors. Participants were recruited between June 2022 and July 2023, and longitudinal data over a consecutive 60-month period preceding enrollment were extracted at 6-month intervals and divided into periods before and during the pandemic. Annual rates of estimated glomerular filtration rate (eGFR) decline were compared between the periods before and during the COVID-19 pandemic using a linear mixed-effects model. The eGFR decline was not accelerated during the pandemic compared with before the pandemic; the estimated eGFR slopes were –1.54 ± 0.28 mL/min/1.73 m2/year before the pandemic and –1.05 ± 0.22 mL/min/1.73 m2/year during the pandemic (p = 0.27). Glycemic control was preserved during the pandemic, despite small but significant increases in body weight, blood pressure, and insulin dose. Exploratory subgroup analyses suggested a less steep eGFR decline during the pandemic among participants with body mass index ≥25 kg/m2 or those receiving renin–angiotensin system inhibitors; however, these findings should be interpreted as hypothesis-generating. In this multicenter cohort of individuals with T1D, the COVID-19 pandemic was not associated with accelerated eGFR decline overall.
SN - 1348-4540
SN - 0918-8959
ER -